Compare Quest Diagnostics Inc (DGX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tapestry, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Tapestry, Inc. trades at $135.74 (market cap $27.35B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | TPR | |
|---|---|---|
Market Cap | $22.80B | $27.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $160.49 |
52-Week Low | $166.42 | $95.69 |
Enterprise Value | $28.82B | $30.20B |
Dividend Yield | 1.67% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TPR is trading at $136.13, down 3.27% today, with a bearish technical signal despite strong analyst support. The company shows impressive profitability with 76.18% gross margins and 55.74% ROE, though recent earnings declined significantly from $816M in 2024 to $183M in 2025. Recent quarters have consistently beaten EPS expectations, with Q1 2026 reporting $1.66 versus $1.30 expected.
The stock presents a compelling growth opportunity with 75.6% analyst buy ratings and a $184.14 consensus target, representing 35% upside. However, elevated P/E of 41.5 and recent net income contraction warrant caution. Key risks include high debt levels and competitive pressures in the luxury retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
